Dr. Coleman: For patients with recurrent ovarian cancer, the main benefit of adding Lifyorli to nab-paclitaxel is controlling ...

More than one-quarter of patients with resistant hypertension had hypercortisolism, suggesting opportunities for screening, ...

A surprising new study reveals that what you eat could play a powerful role in fighting cholera, a deadly diarrheal disease. Researchers found that diets rich in certain proteins—especially casein ...

Data presented at the same congress reinforced cefiderocol's effectiveness against Stenotrophomonas maltophilia, with a subgroup analysis of 119 patients from the PROVE study demonstrating clinical ...

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating ...

Researchers developed an intranasal DNA fusion vaccine targeting drug-tolerant tuberculosis persisters. In preclinical models ...

A new pill called baxdrostat is showing strong results in lowering dangerously high blood pressure in people who don’t respond to standard treatments. In a large global trial, patients saw their blood ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

New real-world evidence on esketamine (Spravato; Janssen Pharmaceutical) nasal spray is reinforcing its role as an effective ...

Climate change, aging populations, and antimicrobial resistance will reshape infection prevention, requiring cross sector collaboration, better data systems, and targeted vaccination by 2040.

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, ...